• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

沙美特罗对慢性阻塞性肺疾病睡眠时血氧饱和度的影响。

Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.

机构信息

Sleep Research Laboratory, St. Vincent's University Hospital, Dublin, Ireland.

出版信息

Respiration. 2010;79(6):475-81. doi: 10.1159/000235619. Epub 2009 Aug 14.

DOI:10.1159/000235619
PMID:19684384
Abstract

BACKGROUND

Sleep is associated with important adverse effects in patients with chronic obstructive pulmonary disease (COPD), such as disturbed sleep quality and gas exchange, including hypoxemia and hypercapnia. The effects of inhaled long-acting beta(2)-agonist therapy (LABA) on these disturbances are unclear.

OBJECTIVES

The aim of the study was to assess the effect of inhaled salmeterol on nocturnal sleeping arterial oxygen saturation (SaO(2)) and sleep quality.

METHODS

In a randomized, double-blind, placebo-controlled, crossover study of moderate/severe stable COPD patients, we compared the effects of 4 weeks of treatment with salmeterol 50 microg b.d. and matching placebo on sleeping SaO(2) and sleep quality. Overnight polysomnography (PSG) was performed at baseline, and after 4 and 8 weeks in addition to detailed pulmonary function testing. Of 15 patients included, 12 completed the trial (median age 69 years, forced expiratory volume in 1 s, FEV(1): 39%).

RESULTS

Both mean SaO(2) [salmeterol vs. placebo: 92.9% (91.2, 94.7) vs. 91.0% (88.9, 94.8); p = 0.016] and the percentage of sleep spent below 90% of SaO(2) [1.8% (0.0, 10.8) vs. 25.6% (0.5, 53.5); p = 0.005] improved significantly with salmeterol. Sleep quality was similar with both salmeterol and placebo on PSG. Static lung volumes, particularly trapped gas volume, tended to improve with salmeterol.

CONCLUSION

We conclude that inhaled LABA therapy improves sleeping SaO(2) without significant change in sleep quality.

摘要

背景

睡眠与慢性阻塞性肺疾病(COPD)患者的许多不良后果相关,如睡眠质量下降和气体交换异常,包括低氧血症和高碳酸血症。目前尚不清楚吸入长效β2-激动剂(LABA)治疗对这些紊乱的影响。

目的

评估沙美特罗对夜间睡眠动脉血氧饱和度(SaO2)和睡眠质量的影响。

方法

在一项中重度稳定 COPD 患者的随机、双盲、安慰剂对照交叉研究中,我们比较了沙美特罗 50μg,每日 2 次(b.d.)和匹配安慰剂治疗 4 周对睡眠 SaO2 和睡眠质量的影响。在基线时、4 周和 8 周时进行了整夜多导睡眠图(PSG)检查,并进行了详细的肺功能检查。15 例患者中,12 例完成了试验(中位年龄 69 岁,第 1 秒用力呼气容积,FEV1:39%)。

结果

平均 SaO2(沙美特罗与安慰剂:92.9%(91.2,94.7)与 91.0%(88.9,94.8);p=0.016)和睡眠时 SaO2 低于 90%的时间百分比(沙美特罗与安慰剂:1.8%(0.0,10.8)与 25.6%(0.5,53.5);p=0.005)均显著改善。PSG 上沙美特罗与安慰剂的睡眠质量相似。静态肺容积,特别是残气量,有改善趋势。

结论

我们的结论是,吸入 LABA 治疗可改善睡眠 SaO2,而对睡眠质量无显著影响。

相似文献

1
Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.沙美特罗对慢性阻塞性肺疾病睡眠时血氧饱和度的影响。
Respiration. 2010;79(6):475-81. doi: 10.1159/000235619. Epub 2009 Aug 14.
2
[Effect of salmeterol in obstructive sleep apnea syndrome].[沙美特罗在阻塞性睡眠呼吸暂停综合征中的作用]
Pneumologie. 1998 Jan;52(1):11-3.
3
Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.布地奈德/福莫特罗与沙美特罗/氟替卡松及沙丁胺醇相比,在慢性阻塞性肺疾病和可逆性气道阻塞患者中起效更快。
Respirology. 2007 Sep;12(5):732-9. doi: 10.1111/j.1440-1843.2007.01132.x.
4
Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.沙美特罗与丙酸氟替卡松在慢性阻塞性肺疾病中起效的早期表现
Thorax. 2005 Apr;60(4):301-4. doi: 10.1136/thx.2004.025411.
5
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.慢性阻塞性肺疾病(COPD)患者从沙美特罗/丙酸氟替卡松联合治疗中撤用丙酸氟替卡松会导致疾病立即且持续恶化:一项随机对照试验
Thorax. 2005 Jun;60(6):480-7. doi: 10.1136/thx.2004.034280.
6
Better adherence to a transdermal tulobuterol patch than inhaled salmeterol in elderly chronic obstructive pulmonary disease patients.老年慢性阻塞性肺疾病患者使用透皮贴剂妥洛特罗较吸入沙美特罗的依从性更好。
Geriatr Gerontol Int. 2013 Apr;13(2):398-404. doi: 10.1111/j.1447-0594.2012.00916.x. Epub 2012 Jul 23.
7
A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.一项双盲交叉研究,比较了慢性阻塞性肺疾病患者中,每日两次服用250/50的氟替卡松/沙丁胺醇持续三周加按需每4小时使用180微克沙丁胺醇与每日两次服用250/50的氟替卡松/沙丁胺醇加按需每4小时使用2喷异丙托溴铵/沙丁胺醇的安全性和有效性。
COPD. 2008 Aug;5(4):221-7. doi: 10.1080/15412550802237408.
8
Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.高剂量沙美特罗治疗囊性纤维化的有效性和耐受性
Pediatr Pulmonol. 2002 Oct;34(4):287-96. doi: 10.1002/ppul.10162.
9
Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD.吸入性糖皮质激素作为α-1抗胰蛋白酶缺乏相关慢性阻塞性肺疾病的附加治疗手段
Respiration. 2008;76(1):61-8. doi: 10.1159/000119718. Epub 2008 Mar 4.
10
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.吸入沙美特罗和氟替卡松:一项比较哮喘单一疗法与联合疗法的研究。
Ann Allergy Asthma Immunol. 1999 Mar;82(3):257-65. doi: 10.1016/S1081-1206(10)62606-3.

引用本文的文献

1
Overlap Syndrome (COPD and OSA): A Treatable Trait for Triple Treatment?重叠综合征(慢性阻塞性肺疾病和阻塞性睡眠呼吸暂停):三联治疗的可治疗特征?
Pulm Ther. 2025 Mar;11(1):1-5. doi: 10.1007/s41030-024-00282-y. Epub 2025 Jan 2.
2
Chronic obstructive pulmonary disease and obstructive sleep apnea overlap: who to treat and how?慢性阻塞性肺疾病与阻塞性睡眠呼吸暂停重叠:谁需要治疗以及如何治疗?
Expert Rev Respir Med. 2024 Jul;18(7):527-537. doi: 10.1080/17476348.2024.2384036. Epub 2024 Aug 2.
3
The Overlap Syndrome: A Combination of Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea.
重叠综合征:慢性阻塞性肺疾病与阻塞性睡眠呼吸暂停的合并症
Cureus. 2024 Jan 16;16(1):e52349. doi: 10.7759/cureus.52349. eCollection 2024 Jan.
4
A review of therapies for the overlap syndrome of obstructive sleep apnea and chronic obstructive pulmonary disease.阻塞性睡眠呼吸暂停与慢性阻塞性肺疾病重叠综合征的治疗综述
FASEB Bioadv. 2021 Jun 11;3(9):683-693. doi: 10.1096/fba.2021-00024. eCollection 2021 Sep.
5
Effect of Triple Therapy with Budesonide-Formoterol-Tiotropium Versus Placebo-Tiotropium on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease.布地奈德-福莫特罗-噻托溴铵三联疗法与安慰剂-噻托溴铵对慢性阻塞性肺疾病患者睡眠质量的影响。
Chronic Obstr Pulm Dis. 2021 Apr 27;8(2):219-229. doi: 10.15326/jcopdf.2020.0178.
6
Sleep in chronic respiratory disease: COPD and hypoventilation disorders.慢性呼吸系统疾病的睡眠:COPD 和通气不足障碍。
Eur Respir Rev. 2019 Sep 25;28(153). doi: 10.1183/16000617.0064-2019. Print 2019 Sep 30.
7
Comorbid obstructive sleep apnoea and chronic obstructive pulmonary disease and the risk of cardiovascular disease.阻塞性睡眠呼吸暂停与慢性阻塞性肺疾病共病及心血管疾病风险
J Thorac Dis. 2018 Dec;10(Suppl 34):S4253-S4261. doi: 10.21037/jtd.2018.10.117.
8
A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.一项旨在确定茚达特罗/格隆溴铵对中重度慢性阻塞性肺疾病患者夜间氧合及症状影响的随机试验:DuoSleep研究。
Int J Chron Obstruct Pulmon Dis. 2019 Jan 9;14:199-210. doi: 10.2147/COPD.S184127. eCollection 2019.
9
The Overlap Syndrome.重叠综合征
Cureus. 2018 Oct 15;10(10):e3453. doi: 10.7759/cureus.3453.
10
Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease.沙美特罗与福莫特罗联合治疗对慢性阻塞性肺疾病小鼠的疗效。
Exp Ther Med. 2018 Feb;15(2):1538-1545. doi: 10.3892/etm.2017.5562. Epub 2017 Nov 24.